CD274 and non-small cell lung carcinoma: Our findings have thus resulted in initiation of the phase 3 LATIFY study (NCT05450692), which compares durvalumab–ceralasertib versus docetaxel for the treatment of patients with NSCLC whose disease progressed during or following prior anti-PD-1/PD-L1 therapy and platinum-based chemotherapy.